Friday, May 13, 2016
CONTINENTAL BREAKFAST
07:00 - 08:00  
Introduction
08:00 - 08:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 9:
08:15 - 09:45

Panels for HBOC – The way forward

CHAIR: Paul Pharaoh, BM, BCh, PhD, University of Cambridge, Cambridge, UK

Cancer susceptibility gene panels: Basic principles

Paul Pharaoh, BM, BCh, PhD, University of Cambridge, Cambridge, UK

Breast and ovarian cancer susceptibility genes: which genes are ready to be included in panels?

Douglas Easton, PhD, University of Cambridge, Cambridge, UK

Proffered Paper 1 : Variant testing post mortem: clinical experience with HBOC gene panel variant testing on more than 300 archival FFPE non-tumor tissue samples, from deceased relatives

Annabeth Petersen, MD, PhD, Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark

Proffered Paper 2 : Analysis of cases and controls raises questions about the clinical utility of extended panel testing for familial breast cancer

Paul James, MBChB, DPhil, FRCAP, Familial Cancer Centre, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Proffered Paper 3 : Breast and ovarian cancer risks beyond BRCA1/2 from a cohort of 15,000 women undergoing multigene panel testing

Jill Dolinsky, RN, MS, CGC, Clinical Diagnostics, Ambry Genetics, Aliso Viejo, CA, USA

Question and discussion period (all speakers)

BREAK
09:45 - 10:15  
SESSION 10:
10:15 - 11:45

New genes, old genes and modifiers

CHAIR: Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

Variants that modify breast and ovarian cancer risk in BRCA1/2 carriers: the CIMBA experience

Georgia Chenevix-Trench, PhD, Head, Cancer Genetics Laboratory, QIMR Berghofer, Brisbane, QLD, Australia

The inherited contribution to triple negative breast cancer: BRCA1, BRCA2 and beyond

Fergus Couch, PhD, Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

Proffered Paper 1 : Heritable epimutations associated with breast cancer risk

Melissa Southey, PhD, Grad Dip Law, FHGSA, FFSc (RCPA), Melissa Southey, PhD, Grad Dip Law, FHGSA, FFSc (RCPA), Department of Pathology, University of Melbourne, Melbourne, VIC, Australia

Proffered Paper 2 : Candidate ovarian cancer susceptibility genes identified from whole exome sequencing of two affected individuals per family from 28 ovarian cancer families

Susan Ramus, PhD, University of New South Wales, Sydney, NSW, Australia

Proffered Paper 3 : The Base Excision Repair (BER) pathway contribute to breast cancer susceptibility

Na Li, Research Division, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Question and discussion period (all speakers)

CLOSING SESSION
11:55 - 13:10

The Marla Miller Memorial Lecture

Introductory Remarks

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

Hereditary breast and ovarian cancer in the era of precision medicine

Francis Collins, MD, PhD, Director, National Institutes of Health, Bethesda, MD, USA

Presentation by the Miller Family

Introductory Remarks

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Marla Miller-Gross
Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.

Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.